We next considered how each class of FOXA1 alteration associated with outcomes based on the first instance of prostate cancer systemic treatment by first-line ADT, second-generation AR signaling inhibitors (ARSI), and taxane chemotherapies (Fig. 4A–C; Supplementary Table S5). Here, AR is linked to prostate cancer.